scholarly journals A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis

2012 ◽  
Vol 103 (5) ◽  
pp. 939-944 ◽  
Author(s):  
Yoshiko Awazu ◽  
Akio Mizutani ◽  
Yoshinori Nagase ◽  
Hidehisa Iwata ◽  
Yuya Oguro ◽  
...  
2019 ◽  
Vol 12 (11) ◽  
pp. e230727 ◽  
Author(s):  
Rodrigo Otavio Lami Pereira ◽  
Payal R Patel ◽  
Pramod K Guru ◽  
Devang K Sanghavi

Pazopanib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) that inhibits the vascular endothelial growth factor receptor A pathway and has the potential to cause ischaemic bowel changes, including perforation. Here we report a case of a 51-year-old man with large, metastatic, retroperitoneal leiomyosarcoma that developed a tumour-bowel fistula after 4 weeks of pazopanib therapy. He presented to the emergency department with sepsis and 1-week history of worsening fever, chills, nausea and diarrhoea. Abdominal CT findings of mesenteric and portal vein gas, commonly found in mesenteric ischaemia and VEGFR modulator-induced bowel toxicity, provided evidence for the causal relation. Unfortunately, the case was not amenable to surgery and patient succumbed to the illness.


Sign in / Sign up

Export Citation Format

Share Document